Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism?

Table 2 Serum phosphorus (P) category at baseline and after treatment (efficacy assessment phase; EAP) by magnitude of PTH reduction at EAP

	PTH reduction ≥30% at EAP (N = 326)	PTH reduction <30% or increase at EAP (N = 213)
P ≤4.5 mg/dL at baseline, n (%)	90 (28)	56 (26)
P ≤4.5 mg/dL at EAP	131 (40)*	49 (23)
P ≤5.5 mg/dL at baseline	182 (56)	115 (54)
P ≤5.5 mg/dL at EAP	222 (68)*	98 (46)

*P < 0.001 vs subgroup with PTH reduction <30% or increase at EAP, Pearson chi-squared test. Last value carried forward imputation (LVCF) was used for patients who did not have iPTH or phosphorus values measured during the EAP.

ISSN: 1471-2369